Actos Now for the prevention of diabetes (ACT NOW) study
Open accessThe DOI matches its Crossref record; 54 of the 57 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
BACKGROUND: Impaired glucose tolerance (IGT) is a prediabetic state. If IGT can be prevented from progressing to overt diabetes, hyperglycemia-related complications can be avoided. The purpose of the present study was to examine whether pioglitazone (ACTOS) can prevent progression of IGT to type 2 diabetes mellitus (T2DM) in a prospective randomized, double blind, placebo controlled trial. METHODS/DESIGN: 602 IGT subjects were identified with OGTT (2-hour plasma glucose = 140-199 mg/dl). In addition, IGT subjects were required to have FPG = 95-125 mg/dl and at least one other high risk characteristic. Prior to randomization all subjects had measurement of ankle-arm blood pressure, systolic/diastolic blood pressure, HbA1C, lipid profile and a subset had frequently sampled intravenous glucose tolerance test (FSIVGTT), DEXA, and ultrasound determination of carotid intima-media thickness (IMT). Following this, subjects were randomized to receive pioglitazone (45 mg/day) or placebo, and returned every 2-3 months for FPG determination and annually for OGTT. Repeat carotid IMT measurement was performed at 18 months and study end. Recruitment took place over 24 months, and subjects were followed for an additional 24 months. At study end (48 months) or at time of diagnosis of diabetes the OGTT, FSIVGTT, DEXA, carotid IMT, and all other measurements were repeated.Primary endpoint is conversion of IGT to T2DM based upon FPG >or= 126 or 2-hour PG >or= 200 mg/dl. Secondary endpoints include whether pioglitazone can: (i) improve glycemic control (ii) enhance insulin sensitivity, (iii) augment beta cell function, (iv) improve risk factors for cardiovascular disease, (v) cause regression/slow progression of carotid IMT, (vi) revert newly diagnosed diabetes to normal glucose tolerance. CONCLUSION: ACT NOW is designed to determine if pioglitazone can prevent/delay progression to diabetes in high risk IGT subjects, and to define the mechanisms (improved insulin sensitivity and/or enhanced beta cell function) via which pioglitazone exerts its beneficial effect on glucose metabolism to prevent/delay onset of T2DM. TRIAL REGISTRATION: clinical trials.gov identifier: NCT00220961.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Internet-based management systems that combine real-time blood glucose monitoring, personalized feedback and educational resources have shown potential in improving outcomes for various chronic diseases (7).”
From Effectiveness of internet-based management in newly diagnosed young adults with type 2 diabetes: a prospective comparative study (2025) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 1×
“The hepatic insulin resistance index was calculated as the FPI × FPG (equivalent to inverse of HOMA) [37].”
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 4×
“Prior to randomization all subjects met with a dietician and received 30 minutes of instruction consistent with the goals of the Diabetes Prevention Program [16].”
InfluentialWild, S., Roglic, G., Green, A., Sicree, R., & King, H. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1047 · Cited by 15,297 · cited 1×
“Background Type 2 diabetes mellitus (T2DM) affects 21 million Americans [1] and approximately 194 million individuals world wide [2] and its prevalence is rapidly increasing [3].”
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 3×
“The DPP [42] cited 21 studies with conversion rates (percent per year) ranging from 2.3% to 11%.”
InfluentialThe Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“The insulin secretion/insulin resistance or disposition index during the OGTT was calculated as I/G × Matsuda index and as I/G × SI [32,36].”
Self-citationEconomic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147 · cited 1×
“The estimated cost for the treatment of T2DM and related complications in year 2007 was 174 billion dollars [ 9 ].”
Gupta, A., & Uribarri, J. (2016) · Hormone Research in Paediatrics · doi:10.1159/000444053 · Cited by 4,006
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · cited 1×
“Pioglitazone and other thiazolidinediones have been shown both to enhance muscle/hepatic/adipocyte insulin sensitivity [23-26] and to improve beta cell function [16,18,27,28].”
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Self-citationWeyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
(2006) · The Lancet · doi:10.1016/s0140-6736(06)69420-8 · Cited by 1,706 · cited 1×
“Recent studies have demonstrated that life style modification [15,16] and therapy with metformin [16] and thiazolidinediones [14,17,18] can prevent or delay the onset of T2DM in high risk subjects.”
The Statistical Analysis of Failure Time Data
Young, W. R. (1981) · Journal of Quality Technology · doi:10.1080/00224065.1981.11978770 · Cited by 1,666
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Self-citationEconomic costs of diabetes in the U.S. in 2007
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-9017 · Cited by 1,323
Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population
Cowie, C. C., Rust, K. F., Byrd-Holt, D. D., Eberhardt, M. S., Flegal, K. M., Engelgau, M. M., Saydah, S. H., Williams, D. E., Geiss, L. S., & Gregg, E. W. (2006) · Diabetes Care · doi:10.2337/dc06-0062 · Cited by 1,210
Gillies, C. L., Abrams, K. R., Lambert, P. C., Cooper, N. J., Sutton, A. J., Hsu, R. T., & Khunti, K. (2007) · BMJ · doi:10.1136/bmj.39063.689375.55 · Cited by 1,171 · cited 1×
“Individuals with impaired glucose tolerance (IGT) represent a high risk group, with a conversion rate that varies from 3–13% per year, depending upon the ethnic group [19].”
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2008) · Diabetes Care · doi:10.2337/dc08-s055 · Cited by 1,062
Toward Physiological Understanding of Glucose Tolerance: Minimal-Model Approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diab.38.12.1512 · Cited by 1,001
Cauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients.
Shichiri, M., Kishikawa, H., Ohkubo, Y., & Wake, N. (2000) · PubMed · Cited by 879
Abdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2179 · Cited by 744
Self-citationCauter, E. V., Mestrez, F., Sturis, J., et al. (1992) · Diabetes · doi:10.2337/diabetes.41.3.368 · Cited by 643
Edelstein, S. L., Knowler, W. C., Bain, R. P., Andres, R., Barrett-Connor, E. L., Dowse, G. K., Haffher, S. M., Pettitt, D. J., Sorkin, J. D., Muller, D. C., et al. (1997) · Diabetes · doi:10.2337/diab.46.4.701 · Cited by 641 · cited 1×
“In addition, they evaluated data sets from six population based cohorts [43].”
Edelstein, S. L., Knowler, W. C., Bain, R. P., Andres, R., Barrett-Connor, E. L., Dowse, G. K., Haffner, S. M., Pettitt, D. J., Sorkin, J. D., Muller, D. C., et al. (1997) · Diabetes · doi:10.2337/diabetes.46.4.701 · Cited by 641
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540 · cited 1×
“Individuals with IGT are characterized by defects in both insulin secretion and insulin sensitivity [20-22].”
Self-citationAbdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500
Self-citationMiyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.710 · Cited by 407 · cited 1×
“Pioglitazone and other thiazolidinediones have been shown both to enhance muscle/hepatic/adipocyte insulin sensitivity [23-26] and to improve beta cell function [16,18,27,28].”
Self-citationXiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Kawakubo, M., & Buchanan, T. A. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1066 · Cited by 402
Self-citationLyssenko, V., Almgren, P., Anevski, D., Perfekt, R., Lahti, K., Nissén, M., Isomaa, B., Forsen, B., Homström, N., Saloranta, C., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.1.166 · Cited by 368 · cited 1×
“The natural history of T2DM has been well defined [ 10- 14 ], starting with a genetic predisposition and progression from normal glucose tolerance with insulin resistance to impaired glucose tolerance with superimposition of beta cell failure on insulin resistance, and eventually to overt T2DM characterized by severe…”
Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2004) · Diabetologia · doi:10.1007/s00125-003-1263-9 · Cited by 338 · cited 2×
“tion of the plasma C-peptide curve [34] and expressed as ISR/G [21,22,35].”
Self-citationThe generation and actions of isoprostanes
Roberts II, L. J., & Morrow, J. D. (1997) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/s0005-2760(96)00162-2 · Cited by 305
Maggs, D. G., Buchanan, T. A., Burant, C. F., Cline, G., Gumbiner, B., Hsueh, W. A., Inzucchi, S., Kelley, D., Nolan, J., Olefsky, J. M., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00002 · Cited by 286 · cited 1×
“Pioglitazone and other thiazolidinediones have been shown both to enhance muscle/hepatic/adipocyte insulin sensitivity [23-26] and to improve beta cell function [16,18,27,28].”
Self-citationThe Natural Course of β-Cell Function in Nondiabetic and Diabetic Individuals
Festa, A., Williams, K., D’Agostino, R., Wagenknecht, L. E., & Haffner, S. M. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-1100 · Cited by 271
The DREAM trial – Authors' reply
Gerstein, H. C., Yusuf, S., & Bosch, J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69829-2 · Cited by 253
Papamichael, C. M., Lekakis, J. P., Stamatelopoulos, K. S., Papaioannou, T. G., Alevizaki, M. K., Cimponeriu, A. T., Kanakakis, J. E., Papapanagiotou, A., Kalofoutis, A. T., & Stamatelopoulos, S. F. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01038-9 · Cited by 229 · cited 1×
“Ankle-arm blood pressure was measured as described by Papamichael et al [31].”
Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach
Bergman, R. N. (1989) · Diabetes · doi:10.2337/diabetes.38.12.1512 · Cited by 215
Thiazolidinediones improve β-cell function in type 2 diabetic patients
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00551.2006 · Cited by 200
Self-citationRole of free fatty acids and insulin in determining free fatty acid and lipid oxidation in man.
Groop, L. C., Bonadonna, R. C., Shank, M., Petrides, A. S., & DeFronzo, R. A. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115005 · Cited by 181 · cited 2×
“Separate life-table estimated cumulative incidence curves will be calculated for the pioglitazone-treated and placebo-treated groups, which will be compared using a logrank test [38,40].”
Self-citationDiabetes Care: Moving (a Little) in the Winds of Change
Fonseca, V. A. (2008) · Diabetes Care · doi:10.2337/dc07-2052 · Cited by 165
Azen, S. P., Peters, R. K., Berkowitz, K. M., Kjos, S. L., Xiang, A. H., & Buchanan, T. A. (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00151-7 · Cited by 153
Self-citationRosiglitazone Improves Downstream Insulin Receptor Signaling in Type 2 Diabetic Patients
Miyazaki, Y., He, H., Mandarino, L. J., & DeFronzo, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.8.1943 · Cited by 135 · cited 1×
“Pioglitazone and other thiazolidinediones have been shown both to enhance muscle/hepatic/adipocyte insulin sensitivity [23-26] and to improve beta cell function [16,18,27,28].”
Self-citationKim, Y.-B., Ciaraldi, T. P., Kong, A., Kim, D., Chu, N., Mohideen, P., Mudaliar, S., Henry, R. R., & Kahn, B. B. (2002) · Diabetes · doi:10.2337/diabetes.51.2.443 · Cited by 129 · cited 1×
“Pioglitazone and other thiazolidinediones have been shown both to enhance muscle/hepatic/adipocyte insulin sensitivity [23-26] and to improve beta cell function [16,18,27,28].”
Self-citationDiagnosis and Classification of Diabetes
(2010) · Wiley eBooks · doi:10.1002/9781444391374.ch3 · Cited by 101
Peduzzi, P., Wittes, J., Detre, K., & Holford, T. (1993) · Statistics in Medicine · doi:10.1002/sim.4780121302 · Cited by 97 · cited 1×
“General Statistical Plan: Analysis of primary and secondary endpoints will utilize the intent-to-treat approach [39].”
Klein, R., Barrett-Connor, E. L., Blunt, B. A., & Wingard, D. L. (1991) · Diabetes Care · doi:10.2337/diacare.14.10.914 · Cited by 62 · cited 2×
“Because of the central role that hyperglycemia plays in the development of both micro- and macrovascular complications [4-8], it follows that interventions designed to prevent or delay the onset of hyperglycemia would be effective in preventing these long term complications.”
Gastaldelli, A., Ferrannini, E., Miyazaki, Y., Matsuda, M., & DeFronzo, R. A. (2004) · Diabetologia · doi:10.1007/s00125-004-1479-3 · Cited by 52
Self-citation(2007) · Diabetes Care · doi:10.2337/dc08-s001 · Cited by 31
Leigh, J. P., Ward, M. M., & Fries, J. F. (1993) · Statistics in Medicine · doi:10.1002/sim.4780121102 · Cited by 29
Lachin, J. M., & Wei, L. J. (1988) · Biometrics · doi:10.2307/2531864 · Cited by 25 · cited 1×
“, rate of change in FPG, 2-hour plasma glucose, HbA1c, plasma lipids, etc) between pioglitazone-treated and placebo-treated groups will be compared by the parametric linear random effects model [41].”
Carotid intima-media thickness as a surrogate end point for coronary artery disease.
Hn, H., Wj, M., & Barth, J. D. (1996) · PubMed · Cited by 22
Cited by
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016
Self-citationPioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766
Self-citationHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 629
Self-citationHandelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Self-citationHandelsman, Y., Mechanick, J. I., Blonde, L., Grunberger, G., Bloomgarden, Z. T., Bray, G. A., Dagogo-Jack, S., Davidson, J. A., Einhorn, D., Ganda, O., et al. (2011) · Endocrine Practice · doi:10.4158/ep.17.s2.1 · Cited by 513
Self-citation
Metadata
- Authors
- DeFronzo, R. A., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S., Henry, R. R., Kitabchi, A. E., Mudaliar, S., Musi, N., Ratner, R., Reaven, P. D., Schwenke, D., Stentz, F. B., & Tripathy, D.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- SUNY Downstate Health Sciences University (US)
- Pennington Biomedical Research Center (US)
- University of Southern California (US)
- Georgetown University (US)
- University of California San Diego (US)
- University of Tennessee Health Science Center (US)
- MedStar Health Research Institute (US)
- Phoenix VA Health Care System (US)
- Corresponding author
- DeFronzo, Ralph A
- ORCID
- Venue
- BMC Endocrine Disorders
- Published
- 2009-07-29
- Volume
- 9
- Issue
- 1
- Pages
- 17-17
- ISSN
- 1472-6823 (ISSN-L)
- PMC
- PMC2725044
- OpenAlex
- W2015852718
- Cited by
- 89
- References
- 54
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 3 · 2016: 3 · 2015: 7 · 2014: 4 · 2013: 7 · 2012: 8
- FWCI
- 11.90
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0 (tdm)
- Locations
- BMC Endocrine Disorders (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- pioglitazone, impaired glucose tolerance, type 2 diabetes prevention, prediabetes, insulin sensitivity, beta-cell function, carotid intima-media thickness, cardiovascular risk factors, glycemic control, glucose metabolism, thiazolidinediones, glucose tolerance test, carotid ultrasound, body composition, HbA1c, lipid profile, blood pressure
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.